NervGen Pharma Corp. announced that the Board of Directors and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & Chief Executive Officer and a member of the Board, effective immediately. The Board of Directors has appointed current Executive Chairman of the Board Bill Radvak as interim CEO.

Mr. Brennan will serve as a strategic advisor to management and the Board during the transition period. The Board has initiated a search for a permanent CEO. Mr. Radvak served as President of NervGen from January 2017 to June 2018.

For over 30 years, Mr. Radvak has been the CEO and director of multiple start-up companies. He was a founder and the CEO of Response Biomedical, a publicly listed medical device company that he led from inception into a sales and manufacturing company. Mr. Radvak received a Bachelor of Applied Science degree from the University of British Columbia.